Study: Non-Psychoactive Plant Cannabinoids Possess Synergistic Anti-Cancer Activity In Leukemia Cell LinesOctober 15, 2013
The concomitant administration of various non-psychoactive plant cannabinoids demonstrates synergistic anti-cancer activity in human leukemia cells, according to preclinical trial data published online this week in the journal Anticancer Research.
Investigators from Saint George’s, University of London assessed the anti-cancer potential of three non-psychoactive cannabinoids (cannabidiol, cannabigerol, and cannabigevarin) and their respective acids on two types of leukaemia cell lines. Authors reported that the administration of cannabinoids in concert with one another resulted in “in additive/mildly synergistic interaction.”
They concluded: “Our findings indicate that cannabinoids act with each other in a way such that doses for therapy could be reduced without a significant loss of activity. … [T]his study adds further support to the idea that cannabinoids can have a role in the cancer setting, not only as single agents, but also in combination with each other.”
Commenting on the study in a press release, lead author Wai Lui said: “These agents are able to interfere with the development of cancerous cells, stopping them in their tracks and preventing them from growing. In some cases, by using specific dosage patterns, they can destroy cancer cells on their own. Used in combination with existing treatment, we could discover some highly effective strategies for tackling cancer. Significantly, these compounds are inexpensive to produce and making better use of their unique properties could result in much more cost effective anti-cancer drugs in future.”
Plant cannabinoids as well as endogenous cannabinoids have been consistently shown to be potent anti-cancer inhibitors in preclinical models, halting the proliferation of glioma cancer cells, prostate cancer cells, breast carcinoma, lung carcinoma, and lymphoma, among other cancer cell lines. NORML’s review of much of this literature appears online here.
An abstract of the study, “Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules,” appears online here.
[Editor's note: This post is excerpted from this week's forthcoming NORML weekly media advisory. To have NORML's news alerts and legislative advisories delivered straight to your in-box, sign up here.]
Some two-thirds of Israeli cancer patients authorized to use cannabis report long-term, symptomatic improvement from the plant, according to clinical data presented in late January at a conference of the Israeli Oncologists Union and reported this week in several international media outlets.
Investigators at the Sheba Medical Center in Tel Aviv, in conjunction with the Israeli Cancer Association, assessed the efficacy of cannabis therapy over the course of one year in 264 patients with cancer. Israeli media reported the findings:
“Some 61 percent of the respondents reported a significant improvement in their quality of life as a result of the medical marijuana, while 56 percent noted an improvement in their ability to manage pain. In general, 67 percent were in favor of the treatment, while 65 percent said they would recommend it to other patients.”
The study concluded that cannabis is an “effective” treatment for certain symptoms of the disease cancer and recommended, “The treatment should be offered to the patients in earlier stages of cancer.”
In the trial, the most common types of cancer for which medical marijuana was authorized was lung cancer (21 percent ), breast cancer (12 percent ) and pancreatic cancer (10 percent ).
The study focused primarily on the use of cannabis to relieve various symptoms of cancer or cancer treatment, such as pain and nausea, but did not evaluate whether marijuana therapy could potentially suppress the proliferation of the disease. In preclinical trials, various cannabinoids – including THC and CBD (cannabidiol) – have been shown to selectively target and eliminate malignant cells and cancerous tumors.
To date, some 6,000 Israelis possess government authorization to use cannabis therapeutically. Patients authorized by the federal program may either cultivate cannabis at home or they may obtain marijuana from one of the nation’s 12 licensed cannabis farms.
Last summer, the Israeli Health Ministry formally acknowledged the therapeutic utility of cannabis and announced newly amended guidelines to more effectively govern the state-sponsored production and distribution of medical marijuana. The Ministry estimates that as many as 40,000 patients will eventually have access to medicinal cannabis once the Israeli program is fully implemented.
NORML’s literature review of the anti-cancer properties of cannabis and cannabinoids is available here.
Tremendous PBS Video Explains Why Medical Cannabis Works — And How Big Pharma Is Planning To Cash In On ItAugust 25, 2011
PBS is to be commended for producing this excellent video summarizing the science behind the use of cannabis as a medicine.
Want to know why cannabis is effective at treating multiple symptoms and conditions? Watch this video. Want to know how cannabinoids selectively target and kill cancer cells? Watch this video. Want to know how many patents Big Pharma has taken out on cannabis-derived synthetic drugs? Watch this video.
And then share it with your friends and family.
Now Dr. Andrew Weil, a best-selling author and world-renowned leader and pioneer in the field of integrative medicine, has lent his powerful voice to this discussion.
Cannabis Rx: Cutting Through the Misinformation
via Huffington Post
[Excerpt below; read the full commentary here.] Research into possible medical uses of cannabis is enjoying a renaissance. In recent years, studies have shown potential for treating nausea, vomiting, premenstrual syndrome, insomnia, migraines, multiple sclerosis, spinal cord injuries, alcohol abuse, collagen-induced arthritis, asthma, atherosclerosis, bipolar disorder, depression, Huntington’s disease, Parkinson’s disease, sickle-cell disease, sleep apnea, Alzheimer’s disease and anorexia nervosa.
But perhaps most exciting, cannabinoids (chemical constituents of Cannabis, the best known being tetrahydrocannabinol or THC) may have a primary role in cancer treatment and prevention. A number of studies have shown that these compounds can inhibit tumor growth in laboratory animal models. In part, this is achieved by inhibiting angiogenesis, the formation of new blood vessels that tumors need in order to grow. What’s more, cannabinoids seem to kill tumor cells without affecting surrounding normal cells. If these findings hold true as research progresses, cannabinoids would demonstrate a huge advantage over conventional chemotherapy agents, which too often destroy normal cells as well as cancer cells.
As long ago as 1975, researchers reported that cannabinoids inhibited the growth of a certain type of lung cancer cell in test tubes and in mice. Since then, laboratory studies have shown that cannabinoids have effects against tumor cells from glioblastoma (a deadly type of brain cancer) as well as those from thyroid cancer¸ leukemia/lymphoma, and skin, uterus, breast, stomach, colorectal, pancreatic and prostate cancers.
… If you want to learn more about this subject, I recommend an excellent documentary film, “What If Cannabis Cured Cancer,” by Len Richmond, which summarizes the remarkable research findings of recent years. Most medical doctors are not aware of this information and its implications for cancer prevention and treatment. The film presents compelling evidence that our current policy on cannabis is counterproductive.
At this past weekend’s national NORML Conference, several panelists — myself included — discussed the use of cannabinoids as selective anti-cancer agents. We also screened Len Richmond’s excellent documentary (in which I’m briefly interviewed) “What If Cannabis Cured Cancer?” (Watch the movie trailer here.)
Fortunately, this important discussion is just now finally making its way into the mainstream. Unfortunately, it’s taken 30+ years to get the MSM to notice.
What possible advancements in the treatment of cancer may have been achieved over the past three decades had U.S. government officials chosen to advance — rather than suppress — clinical research into the anti-cancer effects of cannabis? It’s time for the public and the media to demand an answer.
Investigators and pundits alike are fond of calling for ‘more research’ into the safety and efficacy of marijuana and its active compounds. Ironically, when such calls are heeded and new research is published, nobody wants to talk about it.
For example, researchers at the State University of New York (SUNY), Upstate Medical University in Syracuse published data in the June issue of the journal Pharmacology concluding that the administration of the plant cannabinoids delta-8-THC and delta-9-THC halted cellular respiration and tumor growth in human oral cancer cells. Specifically, investigators reported that cannabinoids were a “potent inhibitor” of Tu183 human cancer cells, a notoriously difficult to treat type of oral cancer.
Of course, this is hardly the first time that pot’s compounds have been demonstrated to possess anti-cancer properties. As has been widely reported here and elsewhere, US government researchers were first aware of this finding over 35 years ago, and today there exist published scientific studies demonstrating that cannabinoids can inhibit the proliferation of a wide range of cancers — including brain cancer, prostate cancer, breast cancer, lung cancer, skin cancer, pancreatic cancer, biliary tract cancer, and lymphoma. Nonetheless, abstract prohibitionist concerns regarding marijuana’s supposed cancer risk continue to dominate the headlines while actual scientific studies debunking these allegations tend to go unnoticed.
Similarly, preclinical data published online last week in the journal Cell Communication and Signaling reported that the administration of the non-psychoactive cannabinoid cannabidiol (CBD) increases adult neurogenesis (the active production of new neurons) in laboratory animals. Authors speculated that cannabis’ pro-neurogenic effects may explain why the plant appears to be useful in the treatment of certain neurodegenerative disorders like Alzheimer’s disease or ALS.
As I wrote last week, to date there are now over 20,000 published studies or reviews in the scientific literature pertaining to marijuana and its active compounds — making marijuana the most studied plant on Earth. But what’s the point in further research if nobody even bothers to pay attention to the research that’s already been done?